Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other serious diseases, announced it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern time. Participants must pre-register for the call, and a live webcast will be available on Lisata's website, remaining accessible for 12 months after the event.
Lisata Therapeutics (Nasdaq: LSTA), una azienda farmaceutica in fase clinica focalizzata nello sviluppo di terapie per tumori solidi avanzati e altre malattie gravi, ha annunciato che pubblicherà i propri risultati finanziari del terzo trimestre 2024 martedì 12 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica alle 16:30 ora dell'Est. I partecipanti devono registrarsi in anticipo per la chiamata, e sarà disponibile un webcast dal vivo sul sito di Lisata, rimanendo accessibile per 12 mesi dopo l'evento.
Lisata Therapeutics (Nasdaq: LSTA), una empresa farmacéutica en etapa clínica centrada en el desarrollo de terapias para tumores sólidos avanzados y otras enfermedades graves, anunció que publicará sus resultados financieros del tercer trimestre de 2024 el martes 12 de noviembre de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica a las 4:30 p.m. hora del Este. Los participantes deben registrarse con anticipación para la llamada, y estará disponible una transmisión en vivo en el sitio web de Lisata, que permanecerá accesible durante 12 meses después del evento.
리사타 테라퓨틱스(Lisata Therapeutics)(나스닥: LSTA)는 임상 단계의 제약 회사로서, 고급 고형 종양 및 기타 중증 질환 치료제를 개발하는 데 중점을 두고 있으며, 2024년 11월 12일 화요일 시장 종료 후 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 회사는 동부 표준시 기준으로 오후 4시 30분에 전화 회의를 개최할 예정입니다. 참가자는 사전에 등록해야 하며, 리사타 웹사이트에서 실시간 웹캐스트가 제공되며, 행사 후 12개월 동안 접근할 수 있습니다.
Lisata Therapeutics (Nasdaq: LSTA), une entreprise pharmaceutique en phase clinique axée sur le développement de thérapies pour les tumeurs solides avancées et d'autres maladies graves, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le mardi 12 novembre 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique à 16h30, heure de l'Est. Les participants doivent s'inscrire à l'avance pour l'appel, et un webinaire en direct sera disponible sur le site de Lisata, accessible pendant 12 mois après l'événement.
Lisata Therapeutics (Nasdaq: LSTA), ein pharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für fortgeschrittene solide Tumore und andere schwere Erkrankungen konzentriert, hat angekündigt, dass es am Dienstag, den 12. November 2024, nach Börsenschluss seine Finanzergebnisse für das dritte Quartal 2024 veröffentlichen wird. Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten. Teilnehmer müssen sich im Voraus für den Anruf registrieren, und ein Live-Stream wird auf der Website von Lisata verfügbar sein, der 12 Monate nach der Veranstaltung zugänglich bleibt.
- None.
- None.
BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
A live webcast of the call will also be accessible under the Investors & News section of Lisata’s website and will be available for replay beginning two hours after the conclusion of the call for 12 months.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s internalizing RGD, or Arginylglycylaspartic acid, (iRGD) cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide’s mechanism of action in our short film. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Media:
ICR Healthcare
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
FAQ
When will Lisata Therapeutics (LSTA) release Q3 2024 earnings?
What time is Lisata Therapeutics (LSTA) Q3 2024 earnings call?
How can I access Lisata Therapeutics (LSTA) Q3 2024 earnings call?
